Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study

Corey A. Siegel; Rupert W. Leong; Jaclyn K. Anderson; Mark Yen; Bin Dong; Bruce E. Sands; Silvio Danese; Brian G. Feagan

doi:10.1016/S0016-5085(25)04412-9

Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study

Corey A. Siegel, Rupert W. Leong, Jaclyn K. Anderson, Mark Yen, Bin Dong, Bruce E. Sands, Silvio Danese, Brian G. Feagan

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	Tu1883
Pages (from-to)	S-1538-S-1539
Number of pages	2
Journal	Gastroenterology
Volume	169
Issue number	1 Supplement
DOIs	https://doi.org/10.1016/S0016-5085(25)04412-9
Publication status	Published - 3 May 2025
Event	Digestive Disease Week - San Diego, Canada Duration: 3 May 2025 → 6 May 2025

Access to Document

10.1016/S0016-5085(25)04412-9

Cite this

Siegel, C. A., Leong, R. W., Anderson, J. K., Yen, M., Dong, B., Sands, B. E., Danese, S., & Feagan, B. G. (2025). Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study. Gastroenterology, 169(1 Supplement), S-1538-S-1539. Article Tu1883. https://doi.org/10.1016/S0016-5085(25)04412-9

@article{40a484a03467421486251548c4e28f52,

title = "Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study",

author = "Siegel, {Corey A.} and Leong, {Rupert W.} and Anderson, {Jaclyn K.} and Mark Yen and Bin Dong and Sands, {Bruce E.} and Silvio Danese and Feagan, {Brian G.}",

year = "2025",

month = may,

day = "3",

doi = "10.1016/S0016-5085(25)04412-9",

language = "English",

volume = "169",

pages = "S--1538--S--1539",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W. B. Saunders",

number = "1 Supplement",

note = "Digestive Disease Week ; Conference date: 03-05-2025 Through 06-05-2025",

}

Siegel, CA, Leong, RW, Anderson, JK, Yen, M, Dong, B, Sands, BE, Danese, S & Feagan, BG 2025, 'Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study', Gastroenterology, vol. 169, no. 1 Supplement, Tu1883, pp. S-1538-S-1539. https://doi.org/10.1016/S0016-5085(25)04412-9

Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease: results from the open-label extension period of the Phase 2 APOLLO-CD study. / Siegel, Corey A.; Leong, Rupert W.; Anderson, Jaclyn K. et al.
In: Gastroenterology, Vol. 169, No. 1 Supplement, Tu1883, 03.05.2025, p. S-1538-S-1539.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Long-term efficacy and safety of intravenous tulisokibart in patients with Crohn's disease

T2 - Digestive Disease Week

AU - Siegel, Corey A.

AU - Leong, Rupert W.

AU - Anderson, Jaclyn K.

AU - Yen, Mark

AU - Dong, Bin

AU - Sands, Bruce E.

AU - Danese, Silvio

AU - Feagan, Brian G.

PY - 2025/5/3

Y1 - 2025/5/3

U2 - 10.1016/S0016-5085(25)04412-9

DO - 10.1016/S0016-5085(25)04412-9

M3 - Meeting abstract

SN - 0016-5085

VL - 169

SP - S-1538-S-1539

JO - Gastroenterology

JF - Gastroenterology

IS - 1 Supplement

M1 - Tu1883

Y2 - 3 May 2025 through 6 May 2025

ER -